Opus Genetics, Inc.
Close on Oct 19, 2026
- Market cap
- $425.49M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 11, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | Before market open | $800.00K | $-0.14 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 12, 2026 | Before market open | $2.20M | $-0.75 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 10, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 12, 2025 | Before market open | $3.10M | $-0.25 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 13, 2025 | After market close | $2.90M | $-0.12 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 15, 2025 | Before market open | $4.40M | $-0.24 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 31, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 12, 2024 | Before market open | $3.90M | $-0.29 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 13, 2024 | Before market open | $1.10M | $-0.30 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 10, 2024 | Before market open | $1.70M | $-0.29 | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 8, 2024 | Before market open | $1.70M | $-0.21 | – |
Press releases
Announcements Opus Genetics filed with the SEC
Opus Genetics Presents Positive Clinical Data from OPGx-BEST1 and OPGx-LCA5 Gene Therapy Programs at Retina in Rio 2026
Regulation FD disclosure · EX-99.1 to Form 8-K
Prediction of Retinal Sensitivity Changes Following Treatment in BEST Disease George Magrath,
Regulation FD disclosure · EX-99.2 to Form 8-K
Gene Therapy For Congenital Leber Amaurosis (LCA5) Dr. Rodrigo Jorge Ribeirão Preto Medical
Regulation FD disclosure · EX-99.3 to Form 8-K
OPGx-BEST1 Gene Therapy Phase 1/2 Study Low Dose Cohort 1 3-month
Regulation FD disclosure · EX-99.1 to Form 8-K
Opus Genetics Announces Positive Low Dose Cohort 1 Data from Phase 1/2 Clinical Trial of OPGx-BEST1 and Successful FDA Type C Meeting
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
OPGx-BEST1 Gene Therapy Phase 1/2 Study Low Dose Cohort 1 3-month
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Opus Genetics Announces Financial Results for
Results of operations · EX-99.1 to Form 8-K
Opus Genetics Highlights Five Gene Therapy Programs Targeting
Regulation FD disclosure · EX-99.1 to Form 8-K
Opus Genetics R&D Science Forum June 16, 2026 | 10:00 AM – 12:00 PM ET
Regulation FD disclosure · EX-99.1 to Form 8-K
Opus Genetics Announces Financial Results for
Results of operations · EX-99.1 to Form 8-K
Opus Genetics Solidifies Leadership Position in Gene Therapy Development for Inherited Retinal Diseases with Strategic Long-Term Financing by
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Opus Genetics Announces Financial Results for
Results of operations · EX-99.1 to Form 8-K
Delivering on the Promise ofGene Therapy for Rare Inherited Retinal
Regulation FD disclosure · EX-99.1 to Form 8-K
Opus Genetics Highlights 2025 Progress
Regulation FD disclosure · EX-99.1 to Form 8-K
Opus Genetics Announces Financial Results for
Results of operations · EX-99.1 to Form 8-K
Opus Genetics Announces $23 Million Registered Direct Offering
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Opus Genetics Announces Successful FDA Meeting Supporting Advancement of OPGx-LCA5 Toward Pivotal Trial for LCA5-Related Inherited Retinal
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5)
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
OPGx-LCA5 Phase 1/2 Trial Results September 30, 2025 Alan,LCA5
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Opus Genetics Appoints Rob Gagnon as Chief Financial Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Opus Genetics Announces Financial Results for
Results of operations · EX-99.1 to Form 8-K
Opus Genetics and the Global RDH12 Alliance Partner to Advance RDH12 Gene Therapy for Inherited Childhood Blindness
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for
Other events · EX-99.1 to Form 8-K
Opus Genetics Awarded Non-Dilutive Funding from the RD Fund to Support Preclinical Development of OPGx-MERTK Program
Regulation FD disclosure · EX-99.1 to Form 8-K
Opus Genetics Announces Financial Results for First Quarter 2025 and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Opus Genetics Announces Financial Results for Full Year 2024
Results of operations · EX-99.1 to Form 8-K
Opus Genetics Announces Financial Results for Third Quarter 2024 and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Ocuphire Pharma Announces Acquisition of Opus Genetics
Material agreement · Acquisition or disposition completed · Results of operations · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Delivering on the Promise of Ophthalmic Gene Therapy for Rare Inherited Retinal
Material agreement · Acquisition or disposition completed · Results of operations · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.2 to Form 8-K
Ocuphire Pharma Announces Financial Results for Second Quarter 2024 and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
NPDR Subset Analysis of ZETA-1 Phase 2 Trial A moderate to severe
Regulation FD disclosure · EX-99.1 to Form 8-K
Ocuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
O c u p h i r e I n v e s t o r P r e s e n t a t i o n M a r c h 2 0 2
Regulation FD disclosure · EX-99.1 to Form 8-K
Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Ocuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Ocuphire Pharma Announces Financial Results for Third Quarter 2023 and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Ocuphire Corporate Presentation November 2023
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Ocuphire Pharma Announces Successful End-of-Phase 2 Meeting with FDA for Oral APX3330 in Diabetic Retinopathy
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Ocuphire Pharma Announces Appointment of George Magrath, M.D., M.B.A., M.S., as Chief Executive Officer and Director
Executive or director change · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Ocuphire Pharma and Viatris Announce FDA Approval of RYZUMVl ™ (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of
Other events · EX-99.1 to Form 8-K